Apyx Medical's AYON System Drives Analyst Upgrades and Revenue Growth Expectations

Apyx Medical's stock price target has risen from $4.50 to $6.00 per share, driven by the successful launch of the AYON system and growing patient reach. Analysts note a decrease in the discount rate and a significant uptick in revenue growth expectations. The company has raised its 2025 revenue guidance to $50.5-$52.5 million, and a new 510(k) notification was submitted to the FDA to expand the AYON Body Contouring indication.